Market Pure-Vu® GEN2 Receives FDA Clearance

PerkinElmer to Acquire In-Vitro Diagnostics Company Immunodiagnostic Systems Holdings PLC

IDS’s portfolio and expertise will seamlessly integrate within EUROIMMUN, a PerkinElmer company since 2017.

Precision Spine Reaches Milestone with the Reform® Modular Pedicle Screw System

The Reform® Modular Pedicle Screw System provides surgeons with increased flexibility, versatility, and visibility to meet the varying requirements of degenerative and trauma procedures.

Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for the second-generation Pure-Vu® System (“Pure-Vu® GEN2”) to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure.

“Inadequate bowel preparation prior to colonoscopy remains an unmet need that affects a significant percentage of patients’ ability to receive a complete and high-quality exam. This often leads to canceled, delayed and aborted procedures, resulting in prolonged hospitalizations and increased costs for both patients and providers,” commented Jason B. Samarasena, MD FACG, Associate Clinical Professor of Medicine, Division of Gastroenterology School of Medicine, University of California Irvine. “The Pure-Vu® System provides an important solution to address the significant clinical challenges and inefficiencies associated with inadequate prep and the Pure-Vu® GEN2 provides an innovative, easy to use platform that enables a streamlined approach to the overall procedure.”

Pure-Vu® GEN2The Pure-Vu® System is a U.S. FDA-cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard and slim colonoscopes to enable safe and rapid cleansing during the procedure while preserving established procedural workflow and techniques. Pure-Vu® GEN2 has been designed to improve the mobility, setup logistics of the system and enhance navigation through the colon, while retaining all the same cleansing functionality as the first generation of the Pure-Vu® System.

“Receiving FDA clearance for our Pure-Vu® GEN2 represents a major milestone for the Company. The Pure-Vu® System continues to demonstrate outstanding cleansing performance in poorly prepped colons, including the statistically significant improvement in colon cleanliness in hospitalized patients as recently demonstrated by the positive outcome of our REDUCE study. With our robust portfolio of health economic and clinical data coupled with 510(k) clearance from the FDA of Pure-Vu® GEN2, we are now well positioned to execute our planned commercial launch of the Pure-Vu® System this year and advance toward our goal of establishing the Pure-Vu® System as a new standard of care in key endoscopy segments,” commented Tim Moran, Chief Executive Officer of Motus GI.

Our planned initial launch will focus on the inpatient colonoscopy market where challenges with insufficient bowel prep slow diagnosis, diminish the quality of care, and add significant costs to hospital systems. Motus GI believes that the Pure-Vu® System may improve quality of care and potentially reduce healthcare costs by reliably and predictably moving patients through the hospital system to a successful examination.



Subscribe to Medical Device News Magazine here.

Related Articles